Copper therapy improves memory and spatial learning

In experiments on Alzheimer’s disease models, the Cu(ATSM) compound helped restore the function of these pumps. Over a 56-day period, the therapy increased the number of P-gp by 24.1%, reduced the level of beta-amyloid by 42%, and improved spatial learning by almost 44%.

Cu(ATSM) is a copper complex with anti-inflammatory and neuroprotective properties. He already has experience in clinical research: he has studied it in Parkinson’s disease and amyotrophic lateral sclerosis, so the drug could potentially move relatively quickly to trials in people with Alzheimer’s disease.

Researchers suggest that the effect is not limited to restoring the blood-brain barrier. It is possible that copper therapy also activates microglia, the brain’s immune cells that can engulf and destroy toxic plaques. While scientists continue to investigate the exact pathways by which proteins are released from the brain into the bloodstream.

Alzheimer’s disease and other forms of dementia are becoming increasingly prevalent global health issues. Therefore, the search for methods to stop the decline in cognitive functions remains extremely important. The findings open up the prospect of using biometallic therapy, in particular, copper-based drugs, to combat impaired brain vascular function and memory loss.